Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Lymphoma Clinical Trials in Michigan | 507 Studies

Clinical Trials LymphomaMichigan

Lymphoma Clinical Trials in Michigan

Find 507 clinical trials for lymphoma near Michigan. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Michigan

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 21-40 of 507 trials

CompletedA Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL).NCT01716806·Birmingham, Alabama and 53 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedA Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaThis study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx)…NCT04182204·Jacksonville, Florida and 61 others

Active not recruitingA Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer.NCT04224493·Mobile, Alabama and 203 others

CompletedA Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced CancerPF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells.NCT00585195·Orange, California and 28 others

CompletedQuality of Life in Children Treated for CancerRATIONALE: Questionnaires that measure quality of life may improve the ability to plan treatment for children with cancer.NCT00005881·Duarte, California and 16 others

RecruitingTegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsThis phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or…NCT04851119·Birmingham, Alabama and 20 others

CompletedEtanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell TransplantThis phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.NCT00309907·Birmingham, Alabama and 25 others

RecruitingNatalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyThis phase II studies how well natalizumab works in preventing immune effector cell associated neurologic syndrome (ICANS) in patients with diffuse large B-cell lymphoma (DLBCL)…NCT07892027·Ann Arbor, Michigan

CompletedMK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaThis phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or…NCT01231919·Birmingham, Alabama and 24 others

Active not recruitingEvolut™ EXPAND TAVR II Pivotal TrialObtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.NCT05149755·Birmingham, Alabama and 93 others

CompletedEfficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid ArthritisThe primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or…NCT03120949·Mesa, Arizona and 238 others

CompletedStudy of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumThe purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent…NCT00896454·Encinitas, California and 23 others

CompletedSWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin LymphomaRATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.NCT01000558·Mobile, Alabama and 202 others

CompletedSDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)SUMMARY: This is an open label study combining Rituxan and SDX-105. Rituxan will be given on day 1 followed by a 30-60 minute intravenous infusion of SDX-105 on day 2 and day 3.NCT00076349·Anchorage, Alaska and 33 others

RecruitingA Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory…NCT06393738·New Haven, Connecticut and 20 others

CompletedStudy of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)This study is to evaluate the safety and anti-tumor activity of ASP3026 in patients with advanced malignancies (solid tumors and B-cell lymphoma).NCT01284192·Orange, California and 5 others

TerminatedStudy of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLA Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1…NCT05153330·Irvine, California and 40 others

CompletedCombination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic LeukemiaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.NCT00005977·Birmingham, Alabama and 118 others

Active not recruitingTelaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic AstrocytomaThis phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or…NCT03528642·Phoenix, Arizona and 24 others

CompletedOpen-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell LymphomasHistorically cutaneous and peripheral T-cell lymphomas have response rates of approximately 30% to standard chemotherapy regimens.NCT02158975·Ann Arbor, Michigan

PreviousPage 2 of 26Next

Other Conditions in Michigan

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia